TNF and rheumatoid arthritis: It is clear that although targeting such immune and inflammatory pathways, especially TNF signaling, is currently used in the clinic, the reversal of systemic bone loss and structural changes in RA by anti‐TNF agents alone does not appear to prevent osteopenic disorders independently of inflammation.